The Kentucky Horse Racing Commission's hearing to address Bob Baffert's appeal came to a crossroad early in its fifth session on Monday in Frankfort, Kentucky following a three-day break over the weekend. After the KHRC closed their case at the start of the session, the appellants began their case by calling for a partial directive verdict in their favor based on their claim that the KHRC never proved how Medina Spirit (Protonico) received the betamethasone that led to his positive test and subsequent disqualification from his 2021 GI Kentucky Derby victory.
“Although we heard the testimony of a veterinary pharmacologist and three analytical chemists, none of the KHRC experts testified that Medina Spirit received an intra-articular injection of betamethasone within 14 days of the race or ever,” said Baffert attorney Joe DeAngelis.
The route of administration that was used when Medina Spirit received the betamethasone has already been a thoroughly-debated point since Baffert first filed the appeal to clear from his record a 90-day suspension (which he has already served earlier this year) and reverse Medina Spirit's disqualification. While Baffert's team of attorneys have said there is no evidence that Medina Spirit received betamethasone via injection and that he instead received the medication topically to treat a skin lesion, the KHRC argues that the route of administration does not matter as betamethasone is a Class C, prohibited substance in any form.
The attorneys volleyed back and forth on this subject, but ultimately hearing officer Clay Patrick opted to deny the partial directive verdict motion and proceed with further witnesses.
While Baffert was present in court for the hearing last week, he was not present in the hearing room on Monday. He is set to appear back as a witness on Tuesday via Zoom, along with Medina Spirit's owner Amr Zedan.
Over a seven hour span on Monday, three scientific experts took to the stand, all virtually, to discuss the details of Medina Spirit's test result findings.
The first witness of the day was Dr. George Maylin, the director of the New York State Equine Drug Testing Lab which was responsible for the court-approved outside testing of Medina Spirit's urine sample last summer. Taking the stand virtually, Maylin's questioning was frequently interrupted due to technical difficulties, but it went on for over two hours.
Baffert attorney Craig Robertson asked Maylin about the procedure used to test Medina Spirit's sample and the results that were found. Maylin reported that the substances found included betamethasone 17-valerate, clotrimazole and a metabolite of clotrimazole. He concluded that all three were components of the topical ointment Otomax. Later asked by Robertson if the injectable form of betamethasone contains clotrimazole, Maylin replied, “Not that I'm aware of.”
Maylin was cross-examined by Jennifer Wolsing, general counsel for the KHRC. Wolsing's questioning focused in on the fact that betamethasone acetate and betamethasone phosphate, which would be found in an illegal injection of betamethasone, were not directly tested for.
“Had there been more urine and more time, more could have been done,” Maylin said. “But the judge wanted an answer in a hurry.”
When the examination was redirected to Robertson at the end of Maylin's time on the witness stand, Maylin concluded that he was confident in the test results and that he believed there was no injected betamethasone in Medina Spirit's system.
After a break for lunch, the Baffert team brought Tom Lomangino to the witness stand. Lomangino has previously served as the Director of the Maryland Racing Commission Laboratory and the Director of USEF Equine Drug Testing and Research Laboratory.
Lomangino worked under Maylin for a brief stint at Cornell University and categorized Maylin as, “Very dedicated. Consummate technician. Good person to work for.”
Brewster asked Lomangino about the Standard Operating Procedures (S.O.P.) that were used for the original testing conducted by Industrial Laboratories of Colorado. When asked if he believed that the original test followed these procedures, Lomangino said, “No. I read something that said the analyst guessed…What we're talking about here is analytical chemistry. You're going to have certified reference material of the exact compound you're trying to find and you're going to compare that to the unknown.”
Lomangino's time on the witness stand went into the details of the S.O.P. for both the initial test through Industrial Laboratories and the second test conducted by the University of California, Davis. Lomangino said he was not confident that S.O.P were followed for either test.
While Wolsing's cross-examination went into Lomangino's qualification as a lab technician and started a deep dive interpreting the graphs from Medina Spirit's UC Davis test, the examination was cut short due to a medical appointment Lomangino had to attend. He will return to the witness stand tomorrow.
The last witness of the day was Dr. Steven Barker, the former head of the laboratory that tests horse samples in Louisiana. Barker was supportive of the results Maylin discussed earlier in the day.
“Let's keep something in mind,” he said. “Dr. Maylin was asked to do the analysis from three different companies. He did not have an existing method before any of the three. He was asked to, in a very short time, develop an analysis for betamethasone valerate, clotrimazole and gentamicin. Those are not typically monitored in equine horse samples…There's nothing routine about this.”
Barker also criticized Dr. Scott Stanley, who, in his testimony last Thursday, said he did not believe that Medina Spirit got betamethasone from a topical ointment.
“Dr. Stanley made a number of egregious errors in interpreting the data and results,” Barker said.
Robertson later asked if Barker had an opinion as to whether the findings reported by the KHRC were the result of an ointment or an injection.
“The evidence clearly shows that it was as prescribed by the veterinarian,” Barker replied. “It was a topical administration of Otomax that contained the [betamethasone] valerate, clotrimazole, and the clotrimazole metabolite. Yes, this had to have been–with the levels in the urine and with the other facts–from a topical administration.”
With the possibility of the hearing meeting its end on Tuesday, the upcoming session is expected to see virtual appearances by Baffert and Zedan, along with Baffert's veterinarian Dr. Vince Baker. From there, Patrick can arrive at his ruling that the KHRC may accept or reject. Hearing officers hired by racing commissions typically take months to issue a written report and recommended findings.
The post Route of Administration Argument Continues in Day 5 of Derby DQ Appeal appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.
Source of original post
